



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1612
	Confirmation 8455	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	11	4,410,700	10/18/83	Rice	546	149
	12	4,794,001	12/27/88	Mehta et al.	424	458
	13	4,882,166	11/21/89	Graham et al.	424	462
	14	4,904,476	02/27/90	Mehta et al.	424	456
	15	4,968,505	11/06/90	Okada et al.	424	400
	16	4,986,987	01/22/91	Ayer et al.	424	473
	17	5,133,974	07/28/92	Paradissis et al.	424	480
	18	5,137,733	08/11/92	Noda et al.	424	497
	19	5,156,850	10/20/92	Wong et al.	424	473
	20	5,158,777	10/27/92	Abramowitz et al.	424	458
	21	5,160,744	11/03/92	Jao et al.	424	473
	22	5,202,128	4/1993	Morella et al.	424	469
	23	5,223,265	06/29/93	Wong	424	473
	24	5,229,131	07/20/93	Amidon et al.	424	451
	25	5,232,705	08/03/93	Wong et al.	424	473
	26	5,236,689	08/17/93	Wong et al.	424	473
	27	5,299,121	03/1994	Brill et al.	364	413.01
	28	5,308,348	05/03/94	Balaban et al.	604	892.1
	29	5,326,570	07/05/94	Rudnic et al.	424	458
	30	5,391,381	02/21/95	Wong et al.	424	473
	31	5,425,950	06/20/95	Dandiker et al.	424	480
	32	5,478,573	12/26/95	Eichel et al.	424	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1612
	Confirmation 8455	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	33	5,496,561	03/05/96	Okada et al.	424	480
	34	5,500,227	03/19/96	Oshlack et al.	424	476
	35	5,512,293	04/1996	Landrau et al.	424	449
	36	5,567,441	10/22/96	Chen	424	494
	37	5,580,578	12/03/96	Oshlack et al.	424	468
	38	5,593,694	01/1999	Hayashida et al.	424	468
	39	5,639,476	06/17/97	Oshlack et al.	424	468
	40	5,672,360	09/30/97	Sackler et al.	424	490
	41	5,922,736	07/13/99	Dariani et al.	514	317
	42	5,936,091	08/1999	Khetani, et al.	546	233
	43	5,965,734	10/12/99	Ramaswamy, et al.	546	233
	44	6,228,398 B1	05/08/01	Devane et al.	424	484
	45	6,255,325 B1	07/03/01	Dariani, et al.	514	317
	46	6,355,656 B1	03/12/02	Zeitlin, et al.	514	317
	47	6,359,139 B1	03/2002	Khetani et al.	546	233
	48	6,528,530 B1	03/04/03	Zeitlin, et al.	514	317
	49	6,602,887 B2	08/05/03	Dariani, et al.	514	317
	50	6,635,284	10/2003	Mehta et al.	424	497
	51	6,730,325 B2	05/04/04	Devane et al.	424	489
	52	6,962,997 B1	11/2005	Khetani	546	233
	53	7,115,631	10/2006	Zeldis et al.	514	317
	54	2002/0132793 A1	09/19/02	Epstein et al.	514	79

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1612
	Confirmation No. 8455	

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	55	93/05769 A1	01/04/93	WO		
	56	98/06380 A2	02/19/98	WO		
	57	98/14168 A2	09/04/98	WO		
	58	99/62496 A1	12/09/99	WO		
	59	2004/026258 A2	04/01/04	WO		
	60	0 636 366 A2	02/01/95	EP		
	61	1 297 368 A	03/1992	CA		
	62	2 368 367 A1	10/12/00	CA		
	63	2 635 460	9/1994	FR (US 4968505) Equiv.		X

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1612
		Confirmation No. 8455	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	64	Avis, K.E., "Parenteral Preparations," <u>Remington's Pharmaceutical Sciences</u> , 16 <sup>th</sup> Ed., Osol, A. (Ed.), <i>Mack Publishing Co.</i> , 1980, 1463-1487	
	65	Berrang, B. et al., "Enantiomeric alpha aminopropiophenones (cathinone): preparation and investigation," <i>J. Org Chem.</i> , 1982, 47(13), 2643-2647	
	66	CAS RN6051-31-6 or RN 3019-58-7	
	67	Dobashi, A. et al., "Enantioselectivity of hydrogen-bond association in liquid-solid chromatography," <i>Journal of Liquid Chromatography</i> , 1986, 9(2&3), 243-267	
	68	Drimmer, E.J., et al., "Desipramine and methylphenidate combination treatment for depression: case report," <i>Am. J. of Psychiatry</i> , 1983, 140(2), 241-242	
	69	Feng, Z. et al., "Molecular determinants of the platelet aggregation inhibitory activity of carbamoylpiperidines," <i>CA</i> 117:111440, 1992	
	70	Ferris, R.M., et al., "A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta," <i>J. of Pharmacology &amp; Experimental Therapeutics</i> , 1972, 181(3), 407-416	
	71	Ferris, R.M., et al., "Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of <i>l</i> -[ <sup>3</sup> H]norepinephrine and [ <sup>3</sup> H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus," <i>J. of Pharmacology &amp; Experimental Therapeutics</i> , 1979, 210(3), 422-428	
	72	Grob, C.S., et al., "Suspected adverse methylphenidate-imipramine interactions in children," <i>J. of Develop. &amp; Behav. Pediatrics</i> , 1986, 7(4), 265-267	
	73	Japan Chem. Soc., "Organic reaction," 1958, 1(18), 504-505 (translation attached)	
	74	Jursic, B. S. et al., "Determination of enantiomeric composition of 1-phenyl-2-(2-piperidinyl)-acetamide. A Routine Method for Evaluation of Enantiomeric Purity of Primary Amides," <i>Tetrahedron: asymmetry</i> , 1994, 5(9), 1711-1716	

EXAMINER

DATE CONSIDERED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1612
	Confirmation No. 8455	

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

75	Kadouch, et al., <i>Neuropsychobiology</i> , 1977, 3(4), 250-255, HCAPLUS Abstract 88:115433
76	Licamele, W.L., et al., "The concurrent use of lithium and methylphenidate in a child," <i>J. of the Am. Acad. Of Child Adolescent Psychiatry</i> , 1989, 28(5), 785-787
77	Morrison, R. T. et al., <i>Organic Chemistry</i> , 3 <sup>rd</sup> Ed., Allyn & Bacon, Inc., 1973, 32-34
78	Ohashi, N. et al., "Acyl(amino)naphthalene derivatives," CA 104:186157, 1985
79	Patrick, K. et al., "Synthesis of deuterium labelled methylphenidate, p-Hydroxymethylphenidate, Ritalinic Acid and p-Hydroxyritalinic Acid," <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1982, 9(4), 485-490
80	Pelham, W. E. et al., "Sustained Release and Standard Methylphenidate Effects on Cognitive and Social Behavior in Children with Attention Deficit Disorder," <i>Pediatrics</i> , October 1987, 80(4), 491-501
81	Physician's Desk Reference, 46 <sup>th</sup> Ed., 1992, 880-881
82	Rapport, M.D., et al., "Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function," <i>J. of the Am. Acad. Of Child Adolescent Psychiatry</i> , 1993, 32(2), 333-342
83	Soares, J. R., "Stereochemical studies on potential central nervous system active agents and studies on the chemistry of some 3-benzoylpiperidines," <i>UMI Dissertations Services</i> , 1971, 1-180
84	Srinivas, N.R., et al., "In vitro hydrolysis of RR,SS- <i>threo</i> -methylphenidate by blood esterases-differential and enantioselective interspecies variability," <i>Chirality</i> , 1991, 3, 99-103
85	Srinivas, N. R., Thesis entitled "Enantioselective Pharmacokinetics of dl- <i>threo</i> -Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder and Healthy Adults," Thesis submission date: April, 1991
86	Sun, Z. et al., "Methylphenidate is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310(2), 469-476

EXAMINER

DATE CONSIDERED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1612
		Confirmation No. 8455	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	87	Tyndale, R.F., et al., "Neuronal cytochrome P450IID1 (Debrisoquine/sparteine-type): potent inhibition of activity by (–)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6," <i>Molecular Pharmacology</i> , 1991, 40(1), 63-68	
	88	Vanderplas, B. et al., "A convenient synthesis of cis-1R-N-benzyl-2S-hydroxymethyl cyclohexylamine," <i>CA</i> 118:101538, 1992	
	89	Volkow, N.D. et al., "Effects of Methylphenidate on Regional Brain Glucose Metabolism in Humans: Relationship to Dopamine D <sub>2</sub> Receptors," <i>Am J Psychiatry</i> , January 1997, 154(1), 50-55	
	90	In the United States District Court For The District of New Jersey, <b>Civil Action No. 04-CV-04030 (FLW)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: Complaint for Patent Infringement with attached Exhibits A,B and C ( <b>December 21, 2006</b> )	
	91	In the United States District Court For The District of New Jersey, <b>Civil Action No. 04-CV-04030 (FLW) and Civil Action No. 06-CV-6154 (FLW)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: First Amended Answer and Counterclaim of Defendant Teva Pharmaceuticals USA, Inc. in Civil Action No. 06-CV-6154 (FLW) ( <b>March 23, 2007</b> )	
	92	In the United States District Court For The District of New Jersey, <b>Civil Action No. 04-cv-04030 (FLW) and Civil Action No. 06-CV-6154 (FLW)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: Plaintiff's Reply to Defendant's First Amended Counterclaim in Civil Action No. 06-CV-6154 (FLW) ( <b>April 12, 2007</b> )	
	93	In the United States District Court For The District of New Jersey, <b>Civil Action No. 06-CV-05818 (SDW)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Abrika Pharmaceuticals, Inc. and Abrika Pharmaceuticals, LLLP: Complaint For Patent Infringement with attached Exhibits A and B ( <b>December 4, 2006</b> )	

EXAMINER

DATE CONSIDERED

<b>Form PTO-1449 Modified</b>		Docket No. CELG-0422	Application No. 10/820,397
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Jerome B. Zeldis, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date April 8, 2004	Group 1612
		Confirmation No. 8455	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	94	In the United States District Court For The District of New Jersey, <b>Civil Action No. 2:06-CV-05818 (SDW)(MCA)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Abrika Pharmaceuticals, Inc. and Abrika Pharmaceuticals, LLLP, Answer and Counterclaim ( <b>June 1, 2007</b> )	
	95	In the United States District Court For The District of New Jersey, <b>Civil Action No. 06-CV-05818 (SDW)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Abrika Pharmaceuticals, Inc. and Abrika Pharmaceuticals, LLLP: Plaintiff's Reply to the Counterclaim ( <b>June 25, 2007</b> )	
	96	In the United States District Court For The District of New Jersey, <b>Civil Action No. 07-CV-04459 (FLW)(JJH)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: Complaint for Patent Infringement with attached Exhibits A-E ( <b>September 14, 2007</b> )	
	97	In the United States District Court For The District of New Jersey, <b>Civil Action No. 2:06-CV-05818</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Abrika Pharmaceuticals, Inc. and Abrika Pharmaceuticals, LLLP: Defendant's First Supplemental Response to Plaintiff Celgene Corporation's Interrogatories Nos. 6-10 ( <b>September 28, 2007</b> )	
	98	In the United States District Court For The District of New Jersey, <b>Civil Action No. 2:07-cv-04819-SDW-MCA</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. KV Pharmaceutical Company: Complaint for Patent Infringement with attached Exhibits A and B ( <b>October 4, 2007</b> )	
	99	In the United States District Court For The District of New Jersey, <b>Civil Action No. 3:07-cv-04854-FLW-JJH</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Intellipharma Corp.: Complaint For Patent Infringement with attached Exhibits A-E ( <b>October 5, 2007</b> )	
	100	In the United States District Court For The District of New Jersey, Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.: Complaint For Patent Infringement with attached Exhibits A and B ( <b>October 31, 2007</b> )	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422	Application No. 10/820,397
	Applicant Jerome B. Zeldis, et al.	
	Filing Date April 8, 2004	Group 1612
	Confirmation No. 8455	

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	101	In the United States District Court For The District of New Jersey, <b>Civil Action No. 04-CV-4030 (SRC)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: Defendant Teva Pharmaceuticals USA, Inc.'s Supplemental Responses to Plaintiff Celgene Corporation's First Set of Interrogatory Nos. 1-2, 4-7 and 10-15 ( <b>July 14, 2005</b> )
	102	In the United States District Court For The District of New Jersey, <b>Civil Action No. 04-CV-4030 (SRC)</b> , Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma A.G. v. Teva Pharmaceuticals USA, Inc.: Defendant Teva Pharmaceuticals USA, Inc.'s Second Supplemental Responses to Plaintiff Celgene Corporation's First Set of Interrogatory Nos. 1, 5, 10-11, and 14 ( <b>August 19, 2005</b> )

EXAMINER

DATE CONSIDERED